David Alain Wohl, MD, Discusses the Cost-Effectiveness of the Single-Tablet HIV Treatment

David Alain Wohl, MD, associate professor, division of infectious diseases, University of North Carolina at Chapel Hill, says cost-effectiveness of the single-tablet HIV regimen is debatable.
Published Online: April 03, 2014
David Alain Wohl, MD, associate professor, division of infectious diseases, University of North Carolina at Chapel Hill, says cost-effectiveness of the single-tablet HIV regimen is debatable. Logistically, he says, most would prefer to take 1 pill a day instead of 1 pill, 3 times a day. However, that 1 pill dosage can cost patients exponentially more.

As well, replacing brand name HIV prescription regimens with generic substitutions can add to the equation. Dr Wohl suggests that being cost-effective requires judicious decision-making about who exactly should receive a single-dose tablet prescription.

“These are tough decisions, and people have to make really almost Solomon-like determinations about what’s best,” he says. “I think if we do break up singe tablet regimens, we should do so in a very informed way—telling people why we’re doing it, helping them understand, and maybe being selective [about who takes the single tablet treatment].”
 
 


Compendia
Clinical Pathways Compendium
COPD Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium
Upcoming Partner Events
May 20-24, 2017
Boston, MA
June 15-16, 2017
Philadelphia, PA
August 16-17, 2017
Philadelphia, PA
October 24-25, 2017
San Francisco, CA